Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/8/4/355/19480798/8-4-355.pdf
Reference21 articles.
1. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma. The Gynecologic Oncology Group experience;Omura;J Clin Oncol,1991
2. Chemotherapy in advanced ovarian cancer. An overview of randomized clinical trials;BMJ,1991
3. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer;Alberts;J Clin Oncol,1992
4. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada clinical trials group;Swenerton;J Clin Oncol,1992
5. Randomized trial in ovarian cancer comparing cisplatin and carboplatin;Mangioni;J Natl Cancer Inst,1989
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer;Journal for ImmunoTherapy of Cancer;2019-07-30
2. Paclitaxel/Platinum combination regimen and alopecia;Journal of Turkish Society of Obstetric and Gynecology;2012
3. The Total Neuropathy Score: A Tool for Measuring Chemotherapy-Induced Peripheral Neuropathy;Oncology Nursing Forum;2008-01-01
4. Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel;Journal of Clinical Oncology;2006-02-01
5. Standard treatment in advanced ovarian cancer in 2005: the state of the art;International Journal of Gynecological Cancer;2005-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3